1. LAIR-1 agonism as a therapy for acute myeloid leukemia
- Author
-
Lovewell, Rustin R., Hong, Junshik, Kundu, Subhadip, Fielder, Carly M., Hu, Qianni, Kim, Kwang Woon, Ramsey, Haley E., Gorska, Agnieszka E., Fuller, Londa S., Tian, Linjie, Kothari, Priyanka, Paucarmayta, Ana, Mason, Emily F., Meza, Ingrid, Manzanarez, Yanira, Bosiacki, Jason, Maloveste, Karla, Mitchell, Ngan, Barbu, Emilia A., Morawski, Aaron, Maloveste, Sebastien, Cusumano, Zac, Patel, Shashank J., Savona, Michael R., Langermann, Solomon, Myint, Han, Flies, Dallas B., and Kim, Tae Kon
- Subjects
STEMCELL Technologies Inc. ,Viral antibodies -- Health aspects -- Analysis ,Collagen -- Analysis -- Health aspects ,B cells -- Analysis -- Health aspects ,Cancer -- Care and treatment ,Diagnostic reagents industry -- Analysis -- Health aspects ,Hematopoietic stem cells -- Health aspects -- Analysis ,Apoptosis -- Analysis -- Health aspects ,Antibodies -- Health aspects -- Analysis ,Health care industry ,Vanderbilt University. Medical Center - Abstract
Effective eradication of leukemic stem cells (LSCs) remains the greatest challenge in treating acute myeloid leukemia (AML). The immune receptor LAIR-1 has been shown to regulate LSC survival; however, the therapeutic potential of this pathway remains unexplored. We developed a therapeutic LAIR-1 agonist antibody, NC525, that induced cell death of LSCs, but not healthy hematopoietic stem cells in vitro, and killed LSCs and AML blasts in both cell- and patient-derived xenograft models. We showed that LAIR-1 agonism drives a unique apoptotic signaling program in leukemic cells that was enhanced in the presence of collagen. NC525 also significantly improved the activity of azacitidine and venetodaxto establish LAIR-1 targeting as a therapeutic strategy for AML that may synergize with standard-of-care therapies., Introduction Acute leukemias are characterized by the uncontrolled production of malignant hematopoietic progenitors. Acute myeloid leukemia (AML) is the most common adult acute leukemia (1). While extensive research has led [...]
- Published
- 2023
- Full Text
- View/download PDF